Objectives Monoclonal antibody-based of cancer therapy has been considered as one of the most successful therapeutic strategies for both haematologic malignancies and solid tumours in the last two decades. Epidermal growth factor receptor (EGFR) family signalling pathways play a key role in the regulation of cell proliferation, survival and differentiation. Hence, anti-EGFR family mAbs is one of the most promising approaches in cancer therapy. Key findings Here, recent advances in anti-EGFR mAb including approved or successfully tested in preclinical and clinical studies have been reviewed. Although we focus on monoclonal antibodies against the EGF receptor, but the mechanisms underlying the effects of EGFR-specific mAb in cancer therapy, to some extend the resistance to existing anti-EGFR therapies and some therapeutic strategies to overcome resistance such as combination of mAbs on different pathways are briefly discussed as well. Summary The EGFR family receptors, is considered as an attractive target for mAb development to inhibit their consecutive activities in tumour growth and resistance. However, due to resistance mechanisms, the combination therapies may become a good candidate for targeting EGFR family receptors.
Introduction
Cancer is considered as one of the leading cause of death worldwide with approximately 8 million deaths each year. Cancer treatments may include surgery, chemotherapy, radiotherapy, hormone therapy and targeted immunotherapy. [1] In immunotherapy, various parts of immune system are applied or the natural immune system of patients is boosted to combat the disease. In comparison to common tumour treatments such as chemotherapy, immunotherapy targets specifically tumour antigens. Recognition of overexpressed proteins as tumour antigens is considered as a major obstacle due to self-tolerance mechanisms. This subsequently results in inefficient immune responses. However, compared to other therapies, safety and efficacy of immunotherapy have recently been improved. Moreover, in the category of cancers targeted therapy, passive immunotherapy has been reached great success. Passive immunotherapy is a well-established approach for cancer patients during the last decades. [2] Among all different formats of this approach, mAbs and their derivatives (fragment antibodies, nanobodies, multispecific Abs, drugconjugated mAbs, immunotoxins and radiolabelled mAbs) are one of the most important.
The first Murine, chimeric, humanized and human mAbs were introduced to medicine in 1986, 1994, 1999 and 2002, respectively. Moreover, the first mAb as drug rituximab, was approved by Food and Drug Administration (FDA) in 1997 for treatment of non-Hodgkin lymphoma. [3] Trastuzumab, the first successful monoclonal anti-EGFR family receptor antibody against Breast Cancer (BC) was FDA approved in 1998 and since then approximately 30 monoclonal antibodies in various formats have been approved for cancer therapy.
Epidermal growth factor receptor family receptors are one of the most important targets for cancer immunotherapy. The EGFR including HER1 (EGFR), HER2, HER3 and HER4 are transmembrane proteins involved in various downstream cellular signalling such as PI3K/AKT and RAS/RAF pathways ( Figure 1 ). Thus, they could be considered as proto-oncogenes and can cooperate in tumour cell proliferation and progression. [4] [5] [6] HER1 and HER2 are mostly low while HER3 and HER4 are moderate to high expressed in all normal cells. Overexpression of the EGFR family members except for HER4 in cancers leads to poor prognosis and outcome. It has been demonstrated that HER1 and HER3 are structurally similar [7] and their heterodimers are more important than other dimers form of EGFR family member involved in cancers. [8] Furthermore, signalling cross-talk between EGFR family receptors and other cell-surface proteins ( Figure 2 ) led to difficulties in cancer immunotherapy.
Several antiepidermal growth factor receptor family (EGFR) mAbs has been approved by FDA and some of them are being investigated in recent clinical trials. Among them, there is no approved anti-HER3 or HER4 mAbs antibody in clinic. Here, we describe the most recent advances in therapeutic anti-EGFR mAb which interfere with EGFR family receptor signalling pathways. Furthermore, the resistance followed the anti-EGFR mAbs administration, were discussed briefly. In addition, Pan-Her as one of the latest strategy to overcome the acquired antiEGFRs resistance has been addressed.
Anit-HER1 mAbs and derivatives

Approved monoclonal antibodies
Nimotuzumab (THERACIM)
Nimotuzumab is a humanized mAb, targeting the domain III of HER1, resulting in tumour cell growth inhibition by two mechanisms of action; first competing with EGF and TNF-a in binding to receptor due to its high binding affinity to HER1. [9] [10] [11] Second mechanism is blocking the HER1 signalling pathway which results in interfering with aberrant growth signals and/or triggering cell apoptosis. [11, 12] It has been approved for head and neck, glioma and pancreatic cancers (Table 1) . It has been also demonstrated that nimotuzumab sensitizes non-small cell lung cancer (NSCLC) cell lines to radiotherapy. [12] Therefore, it seems combination of nimotuzumab and current chemoradiotherapy, make it an attractive therapeutic approach for treatment of locally advanced nasopharyngeal carcinoma. It has been demonstrated that nimotuzumab induces mild side effects which could be waived. [13, 14] 
Cetuximab (ERBITUX)
Cetuximab is a chimeric mAb targeting domain III of HER1 and approved for treatment of colorectal cancers (Table 1 ). Due to its higher HER1binding affinity than TGF and EGF, following receptor binding, phosphorylation will be induced [15] [16] [17] [18] which can potentially lead to modification of biological responses, interfering with aberrant growth signals and/or triggering cell apoptosis. [10, 19, 20] Furthermore, this mAb is capable of other classical antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity which improve the mAb therapeutic efficacy in treatment of malignant tumours. [21] [22] [23] [24] [25] In addition to these, cetuximab is the only effective mAb for relapse or metastatic cancers. This could be achieved via reduction of matrix metalloproteinases expression which involved in cell adhesion. [25] Encouraging results were obtained from using cetuximab for pancreatic cancer in phase II clinical trial. [26] Based on their results, cetuximab was effectively combined with chemotherapy and the efficacy of chemotherapy was improved. [21, 25] Similarly in another study combination of cetuximab, chemotherapy and radiotherapy led to tumour depletion in nude mice. [25] Moreover, it has been demonstrated that cetuximab could enhance radio sensitivity of squamous cell head and neck cancer cell lines in vitro leading to more apoptosis following radiotherapy. [25] Cetuximab side effects include skin toxicity and papulopustular. [27, 28] Severe toxicity has been reported only in about 10% of patients. [28] 
Panitumumab (VECTIBIX)
Panitumumab is a human mAb binding to domain III of HER1 and was approved for advanced colorectal cancer therapy in 2006. [29] It induces cell cycle arrest at G0/G1 interphase by blocking HER1, and subsequently induces cell death or block proliferation, [15] also it induces ADCC in tumour cells. [30, 31] Panitumumab and cetuximab bind to HER1 with high affinity, therefore interfere with ligand binding, subsequent signalling and HER1 homo/ heterodimerization. It is worth noting that passive immunotherapy with cetuximab or panitumumab individually in metastatic colorectal cancer (CRC), led to resistance; whereas similar to pertuzumab and trastuzumab in Breast cancer patients, combination of cetuximab and panitumumab has synergic effects. These mAbs target two different non-overlapping epitopes [32, 33] and cetuximab binds to EGFR with higher affinity than panitumumab. [34] Hypomagnesaemia has been demonstrated in cetuximab and panitumumab therapies as side effect. [35] Necitumumab (PORTRAZZA)
Necitumumab is a human IgG1 mAb which binds to domain III of HER1 receptors. It inhibits proliferation and propagation of pancreatic, colorectal or lung cancer cell lines. In lung cancer models, similar to cetuximab, necitumumab promotes HER1 internalization and degradation. Also ADCC in NSCLC cell lines has been reported. [31] Figure 2 EGFR family cross-talk in cancer cells. In addition to the homodimer formation, EGFR family receptor can form different heterodimers. For instance HER2-HER3 has a binding site with a 100 fold times more affinity to HRG in comparison with HER3 to HRG. Also, EGFR family receptors are able to cross-talk in down-stream signalling. HER1-HER3, HER2-HER3 and heterodimers activate PI3K/AKT downstream signalling which has a crucial role in resistance to anti-EGFR family targeted therapy. Moreover, as shown above, targeting one receptor can be surrogated with other receptors and consequent signalling. EGFR, epidermal growth factor receptor. [Colour figure can be viewed at wileyonlinelibrary.com] 
Anit-HER1 mAbs in clinical trials
Zalutumumab
Zalutumumab is a human mAb that binds to domain III of HER1 and inhibits ligands binding, receptor dimerization and subsequent conformational change which is needed for receptor activation. [21, 36] Hence, interfere the receptorassociated signalling pathways. [37, 38] Moreover, Zalutumumab is capable of ADCC [37] [38] [39] and following receptor internalizing, HER1 expression is reduced on the cell surface. [37] Duligotuzumab Duligotuzumab is a humanized mAb consisting of two identical Fabs which bind to two non-overlapping different epitopes on HER1/HER3 and inhibit HER1 and HER3 ligand binding [21, 40] which led to inhibition of subsequent HER/ErbB signalling pathways such as AKT/MAPK. [41] Also, it has been demonstrated that duligotuzumab inhibits growth of tumour cells such as colorectal, head and neck, cetuximab-resistant NSCLC cell lines [42] and triple negative BC. [8] It also induces ADCC in tumour cells both in vivo and in vitro. [7, 8, 33, 40, 41, 43] It has been under investigation in phase II clinical trial for SCCHN patients. [36] Matuzumab Matuzumab is a human mAb binding to HER1 and prevents conformational changes. Since conformational changes are crucially needed for receptor activation and subsequent downstream signalling. [25, 44] It shows antitumour activities in vivo and in vitro in xenograft models. Furthermore in different studies, it has been demonstrated that Matuzumab induces ADCC in head and neck cell lines in vitro. [44] [45] [46] [47] [48] As mentioned before, cetuximab and zalutumumab inhibit ligand binding [49] whereas Matuzumab inhibits conformational changes and interferes the receptor-associated transmembrane signalling pathways. Following matuzumab administration mild rash has been reported in clinical trials. [50] Laprituximab emtansine (IMGN-289)
Laprituximab emtansine is an immunotoxin targeting HER1 in phase I clinical trial. [51] [52] [53] [54] [55] Laprituximab is more potent in elimination of tumour cells compared with cetuximab [56] or laprituximab [56, 57] due to containing DM1(a cytotoxic agent inhibits the assembly of microtubules during cell mitosis). [58] Hence, it blocks HER1 signalling and induces cytotoxicity simultaneously. [57] Also, it has been demonstrated that this immunotoxins eliminate NSCLC normal cell lines, [59] or resistant cell lines [56] such as SCCHN cetuximab-resistant cell lines. [60] It can also prevent tumour growth, in HER1-independent manner, hence IMGN-289 overcomes some resistant cell lines. [57] Imgatuzumab (GA-201)
Imgatuzumab, a humanized mAb targeting HER1, is under investigation for solid tumours in phase II clinical trial. [61] Imgatuzumab is a glycoengineered antibody to enhance the potential of ADCC and therefore the efficacy. [18, 62] Furthermore, it has been demonstrated that similar to cetuximab, it is able to eliminate tumour cells through apoptosis. [61, 63] 
Modotuximab
Modotuximab is a 1 : 1 mixture of two individual mAbs which targets two non-overlapping HER1 epitopes in domain III. [64, 65] These two antibodies have synergetic effects in receptor degradation and antitumour activity in animal model. [18] Following the modotuximab binding to HER1, it is rapidly internalized and degraded. [65] [66] [67] Hence, the cell surface HER1 density will be reduced. [18] Despite the cetuximab and panitumumab, modotuximab binds effectively to mutant HER1 and blocks the subsequent signalling. [64] Hence, its in vitro antiproliferative activity is more effective in comparison to cetuximab and panitumumab. [66] Moreover, encouraging results has been achieved in different studies for cetuximab-resistant and metastatic colorectal cancer patients. [64] The other Anit-HER1 antibody formats
ScFv-1171
Anti-HER1 ScFv is a derivative of panitumumab conjugated to a mutant granzyme B. Granzyme B is a serine protease expressed in T and NK cells. Entry of granzyme B into the cytosol, led to perforin formation, simultaneously it triggers proteolytic cascades and consequently induces apoptosis. Granzyme B is a good candidate for tumour cell killing and triggering apoptotic pathways as well. [68] Moreover, Some scFv derivatives of panitumumab or cetuximab fused with pseudomonas toxin show great antitumour capacity in TNBC, pancreatic cancer cells and other cell lines. [69] Anti-EGFR ligands immunotoxins EGF-DT or TGF-a PE-40 are two ligand immunotoxins that target some HER1 overexpressing tumour cell lines in vitro. Following the binding to HER1, they enter into the trafficking pathways then, toxins are translocated into the cytoplasm and cause cytotoxicity followed by death of the target cell. Both PE and DT block ribosome protein translation in cells. [70] Anit-HER2 mAbs and derivatives
Approved monoclonal antibodies
Trastuzumab (HERCEPTIN)
Trastuzumab is a humanized monoclonal antibody which binds to domain IV of HER2. Trastuzumab is the first approved mAb for HER2 + Breast cancer and to be administered alone or with other medicines to treat adenocarcinoma of the stomach or gastroesophageal junction. Clinical application of trastuzumab in combination with chemotherapy, prolongs early and metastatic stages of HER2 + survival. Additionally, in combination with chemotherapeutic agents, trastuzumab inhibits angiogenesis and decreases microvessel density. Also, it depletes tumour specific CD4 + CD25 + regulatory T (Treg) cells. [71] [72] [73] The function of trastuzumab is mediated through Fab or FC fragments. ADCC is the most probable mechanism and trastuzumab facilitates ADCC by recruiting MQ and NK cells. [34, 71] Trastuzumab prevents ligand-independent HER2 dimerization and HER2 heterodimerization with other HER2 family members. [71, 73, 74] It can also down-regulates HER2 expression levels, resulting in G1 arrest through further stabilization and control of different protein kinases such as CDK inhibitor p27(KIP1). [75] [76] [77] Moreover, it blocks HER2 downstream signalling such as PI3K pathway. [74, 78] Trastuzumab also inhibits P95 complex formation in p95-HER2-positive breast tumours. [79] It has been well-established that trastuzumab decreases HER2 density on cell surfaces by endocytosis, internalizing of HER2 and subsequent intracellular degradation. [80, 81] It also inhibits HER2 shedding and metalloproteinase activity by decrease PTEN phosphorylation or AKT de-phosphorylation to induce tumour cells death. [79] Cardiotoxicity is a major reported side effect in trastuzumab-treated patients and in some cases led to stop the antibody administration. [82, 83] 
Pertuzumab (PERJETA)
Pertuzumab is a humanized monoclonal antibody which binds to domain II of HER2. Pertuzumab is an approved mAb only in combination with trastuzumab and docetaxel or taxane for HER2 + Breast cancer-targeted therapy. In fact, trastuzumab and pertuzumab act synergistically. Combination of them inhibits HER2 overexpressing cell lines growth in vivo and in vitro. [10, 84] For resistant trastuzumab metastatic and advanced stages of HER2 + BC, Pertuzumab plus trastuzumab is considered as a useful strategy. [85] It is worth noting that Pertuzumab and trastuzumab bind to different domains of HER2. [71, 84, 86] Pertuzumab inhibits HER2 dimerization with other activated HER-family members such as HER3. [71, 85] Similar to trastuzumab, pertuzumab induce ADCC. [85] HER2/HER3 heterodimerization is an important advantage of pertuzumab in comparison to trastuzumab. [18] Similar to trastuzumab, pertuzumab also induces cardiotoxicity in some patients. [87] Trastuzumab emtansine (KADCYLA)
Ado-trastuzumab-Emtansine is a DM1-conjugated trastuzumab targeting HER2 mAb. Ado-trastuzumab-Emtansine is an FDA approved mAb for treatment of metastatic HER2 + BC. [78] DM1 is a derivative of maytansine and a tubulin inhibitor which inhibit microtubule assembly and subsequently mitotic cell arrest in premetaphase/metaphase phase. On the other hand, similar to pertuzumab and trastuzumab, DM1 induces ADCC. [18, 88] Moreover, conjugated mAb with drugs, toxins or radioactive particles eliminate tumour cells directly. [89] 
Anit-HER2 mAbs in clinical trials
Ertumaxomab
Ertumaxomab is a tri-functional bispecific Ab consisting of anti-HER2, anti-CD3 and the Fcc-receptors I, IIa, and III forming a tri-cell complex between tumour cell, T cell and accessory cells. It results in T cells or MQ or DC activation throughout the Fc part. Ertumaxomab kills HER2 + cells. It also could be effective in trastuzumab-resistant patients and those tumour cells with low level HER2 expression. [79, 90] T-cell activation is not dependent on HER2 expression levels, hence it can be also useful in HER2 low expressing tumour cells, resistant tumour cells or cancer stem cells. [4, 91] 
MM-111
MM-111 is a bispecific Ab, consisting of two anti-HER2 and HER3 scFv [41] and blocks subsequent signalling pathways. [33, 92] HER2 scFv targets tumour cells and HER3 scFv inhibits heregulin (HRG) binding to HER3 and signalling. [8, 41, 93] Moreover, MM-111 inhibits Neuregulin (NRG)-dependent tumour cells proliferation. This effect is dependent on HER3 expression levels. Since it could not block both receptors completely, it should be used in combination with trastuzumab or lapatinib. [7, 42] Antiproliferative effects on some Breast cancer xenograft models have been shown and now it has been investigated in phase II clinical trials for HER2 + /HER3 + Breast cancer patients.
Margetuximab
Margetuximab is an Fc-optimized monoclonal antibody that targets HER2 in breast, gastroesophageal, bladder and other forms of solid tumour cancers. Margetuximab is a chimeric Fc-engineered anti-HER2 mAb with high affinity to FccRIIIa and low affinity to FccRII. Its antitumour activities are similar to trastuzumab whereas ADCC in HER2 + Breast cancer tumour cells in vivo and in vitro [94] is enhanced due to engineered Fc part.
DARPin-PE40 and 4D5 ScFv-PE40
DARPins are engineered, non-immunoglobulin scaffold proteins, which bind to target proteins with high affinity and specificity. DARPins are more compact than scFv and are thermodynamically stable. They do not need VH-VL pairing to bind targets specifically. [95] They do not contain cysteine; hence, they are resistant to protease and can be expressed in bacteria. Because of their small size, penetrate better in tumour cells. [96] A recombinant toxin fused DARPins was used against HER2 + Breast cancer xenograft mouse. DARPin fragment targets HER2 and pseudomonas exotoxin40 (PE40) kills them. 4D5 also shows antitumour activity. [96] Anit-HER3 mAbs and derivatives in clinical trial
MM-121 (Seribantumab)
Seribantumab is a human bispecific Ab targeting HER1 and HER3. It inhibits HER2/HER3 ligand dimerization, HRG1-induced HER3 activation/phosphorylation and consequent signalling. [7, 8, 97, 98] MM-121 reduces HER3 surface density on tumour cells. [33, 97] It is effective on low-level HER2 expression and also on high HRG level expression patients. Furthermore, it has been demonstrated that resistant ovarian cells obtained from ascites can be sensitized to paclitaxel by Seribantumab. [42] Patritumab Patritumab is a human anti-HER3 mAb which binds to extracellular domain of HER3 and results in receptor internalizing and degradation. [33, [98] [99] [100] [101] Also, it inhibits ligand induced dimerization of HER3. Hence, the consequent signalling cascade through HER3/heregulin complex will be inhibited. [42, 99] This inhibitory effects on tumour growth in pancreatic cells, NSCLC and CRC xenograft models have been reported in various studies. [33, [99] [100] [101] [102] It has been demonstrated that Patritumab is more efficient in inhibition of tumour cell lines proliferation compared to cetuximab in vivo and in vitro. [7] Furthermore, in combination with anti-HER2 therapies, trastuzumab-resistant cell lines have been reported to be eliminated by Patritumab in vitro. [101] Furthermore, patritumab and panitumumab showed synergetic effect in some xenograft models. [42] Lumretuzumab Lumretuzumab is a humanized Fc glycoengineered mAb, with improved ADCC due to its approximately 50 times more affinity to FccRIIIa than standard IgG1. [93] Lumretuzumab is used for HER2À/HER3+ metastatic Breast cancer. [33] Depending on HER3 density on tumour cells, the ADCC response would be different. [33, 49, 100] It also inhibits HER3 activation and subsequent signalling. Its efficacy in combination with anti-HER1 or anti-Her2 will be increased. [42] Moreover, MM-121, lumretuzumab and patritumab targets HER3 and their efficacy in combination together will be improved in HER2À/HER3+ Breast cancer patients (Tables 2 and 3) .
Elgemtumab
Elgemtumab is a human mAb binding to epitopes between domain II and IV of HER3. It blocks inactive form of HER3 in a way of ligand-dependent or independent HER3. [93, 103] Hence, HER3 phosphorylation and AKT signalling have been inhibited which consequently lead to the tumour elimination. [7, 33, 104] It is more effective when HER3 activates HER2. [7, 33, 42, 98, 103, 104] It also inhibits ligand-mediated proliferation in HER2 overexpressed, [7] or NRG + cell lines. [8] It is worth noting that Elgemtumab, does not block HRG binding to HER3, therefore there is no effect on HER3/HRG interactions. Elgemtumab shows synergetic effect in combination with trastuzumab or cetuximab on various cell lines. [42] MM-141 MM-141 is a tetravalent Ab which targets HER3, IGFR, NRG and IGF 1and 2. It blocks AKT/PI3k signalling [8, 42, 105] which are involved in metabolic and proliferative pathways in cancer cells. [42] Moreover, it reduces HER3 and IGFR expression levels on pancreatic cell lines. [10] Resistance to therapeutic anti-EGFR monoclonal antibodies
Monoclonal antibody-based treatment of cancer has been established as one of the therapeutic strategies in the last century. Despite all great success in targeted therapy of cancer, resistance to mAb has become a major issue recently. Resistance to mAb is divided to primary resistance such as solid tumours or acquired resistance. [71] EGFR family receptors cross-talks of signalling are considered as a major obstacle in anti-EGFR family receptors therapy. Although individually targeting of HER1, HER2 or HER3 has been successfully entered into clinic, cell death or block proliferation by interfering the receptor associated transmembrane signalling pathways encountered with cross-talks of other EGFR family members (Figure 2 ). [71, 106] As mentioned above, herceptin is one of the most important anti-EGFR family agents, but several BC patients have shown resistance at the first year of therapy. The ErbB family, trigger PI3K and MAPK pathways, which are important for cellular growth, survival and development. [107] They also involve in poor prognosis and resistance development in cancer therapy. Since PI3K signalling is remarkably involved in survival, growth and progression of cancer cells, aberrantly activation of these intracellular signalling (PI3-AKT, MEK and ERK) in herceptin-sensitive tumour cells led to resistance development. [77] A variety of preclinical data have been demonstrated that trastuzumab resistance correlates with increased activation of PI3K pathway induced by aberrantly expressed PTEN. [108, 109] PTEN preferentially dephosphorylates phosphoinositide substrates and negatively regulates AKT/PKB signalling pathway. In addition, PTEN interacts with activated non-receptor tyrosine kinase C-SRC and cause trastuzumab resistance in BC cells. [110] It has also been demonstrated that trastuzumab resistance could be the result of structural changes in HER2/trastuzumab interactions. Furthermore, modification of regulator proteins or growth factor receptors like IGF-1 and their ligands, may lead to the trastuzumab resistance. [111] Enhanced activation of various growth factor signalling pathways and their further cross-talk with HER2, have been considered as the most important pathways involved in development of trastuzumab resistance. So far, pertuzumab and T-DM1 were used to overcome herceptin resistance. [112] In addition to breast, herceptin resistance has been reported in gastric cancer patients as well. [113] All in all, more investigations are required to precisely determine the association between using mAbs, such as herceptin and resistance pathways development to find a desirable approach in suppression of constitutive HER2 activation and trastuzumab sensitization of BC cells. Except for erbB family-related pathways, several other mechanisms may be involved in herceptin resistance of tumour cells. As mentioned in Figure 2 , HER2/HER3 heterodimer plays an important role in acquired resistance of tumours. HER3 is the most potent activator of PI3K/AKT signalling pathway which is important for proliferation, survival and resistance of tumour cells. [114, 115] Moreover, IGFR and p95-HER2 have significant effects in resistance to herceptin. [71, 116, 117] In Pertuzumab-resistant tumour cells, HER1/HER3 heterodimer activates AKT and ERK1/2 signalling. [1] In the case of T-DM1 resistant cells, incomplete HER2 internalization results in insufficient accumulation of DM1 in cytosol and inhibition of DM1 activity. [118] Additionally, NRG (HER3 ligand) can also cause T-DM1 resistance by facilitating the formation of HER2/HER3 complex. [119] It has been demonstrated that acquired resistant to targeted therapeutic agents is not limited to Herceptin. For example, 2 years after introduction of cetuximab in 2004, resistance in NSCLC and colorectal cancer patients were reported in 2006. [120, 121] Furthermore, various proteins such as HER2, KRAS, NRAS, BRAF and MEK have been shown to participate in cetuximab resistance. [122] [123] [124] Similar to cetuximab, panitumumab resistance has been reported. Furthermore, it has been demonstrated that mutation in extracellular domain of EGFR results in acquired resistance of both panitumumab and cetuximab (Figure 3) .
Recently, it has been proposed that homo and heterocombination may be involved in elimination of resistance in EGFR family receptor-positive cancers. Homocombination is a targeting of two or more epitopes of an antigen. In contrast, heterocombination is targeting of several antigens simultaneously. [125, 126] Recently, different studies have indicated that homocombination of HER1 or HER2 through synergistic effect of targeting two different Abs against an antigen is a successful strategy. In this regards, the synergistic effect of pertuzumab and trastuzumab has been approved. [10, 84, 127, 128] As described before, more receptor endocytosis and antitumour activities have been shown in panitumumab and cetuximab combination in comparison to using each of them individually. Bispecific mAb or the other mAb fragments, are more potent in antitumour activity, also these alternative mAb formats can be used in homocombination. For example, biparatopic nanobody containing cetuximab and matuzumab (described before) can specifically inhibit tumour growth in animal xenograft models. [129] [130] [131] Hence, by using alternative mAb fragments such as bispecific scFv, not only tumour targeting becomes more efficient but also side effects such as aggregation in liver, can be avoided. Another strategy for EGFR family receptors targeting is pan-Her. [132] It is a mixture of various antibodies simultaneously targeting different Her family members and consequently tumour growth inhibition. Moreover, the inhibition growth of the cetuximab, pertuzumab and trastuzumab-resistant cell lines treated by pan-Her has been reported. [133] Also, decreased expression levels of all EGFR member receptors without any cross-talk signalling and despite the presence of EGFR member receptors ligands the growth inhibition of these cell lines have been demonstrated. [134] It is worth noting that tumour resistance has been shown to be reduced following pan-HER targeting. Tumour cell treatment with a mixture of antibodies or multispecific mAbs against various epitopes of EGFR, or related family member ErbB2, results in enhanced receptor internalization and degradation. This may subsequently led to the enhanced antitumour activities of these therapeutic antibodies. Hence, they can be considered as good candidates for targeting various tumour markers with a synergistic antitumour effects.
Conclusion
The EGFR family receptors, is considered as an attractive target for mAb development to inhibit their consecutive activities in tumour growth and resistance. As discussed before, among various receptors involved in tumour cell progression, targeting EGFR family members by mAbs is the most valuable strategy. With respect to the important role of EGFR family receptors in carcinogenesis, additional data and more studies are needed to increase our knowledge on the downstream intracellular signalling and anti-EGFR family antibodies resistance before and during the treatment to improve the overall survival.
